Why did ALVAL.PA stock drop today?

ALVAL.PA stock fell **9.77%** due to profit-taking after a strong run, thin liquidity, and pre-earnings uncertainty ahead of the **02 Mar 2026** results. No new corporate release explained the move, making clinical-readout risk the likely driver.

What are the near-term catalysts for ALVAL.PA stock?

Near-term catalysts include the **02 Mar 2026** earnings announcement and any updates on Phase II/III trials for TOTUM-63 and TOTUM-854. Partnership news or cash updates with Nestle9 Health Science could also move ALVAL.PA stock.

What does Meyka AI forecast for ALVAL.PA stock?

Meyka AI's forecast model projects **monthly €0.88** and **quarterly €1.02**, implying downside of **-19.27%** and **-6.42%** from **€1.09**. Forecasts are model-based projections and not guarantees.

Is ALVAL.PA stock a buy after the drop?

ALVAL.PA stock remains high-risk. Meyka AI grades it **B (62.27)** with a HOLD suggestion based on sector and financial factors. Consider risk tolerance, potential trial outcomes and limited liquidity before adding exposure.

EU Stocks

ALVAL.PA Valbiotis SA EURONEXT down 9.77% to €1.09 on 06 Feb 2026: what to watch next

ByDanny Kontos February 7, 2026February 7, 2026

ALVAL.PA stock closed the EURONEXT session on 06 Feb 2026 down 9.77% at €1.09, making it one of today’s top losers in Europe. Liquidity was above average with 383,510 shares traded, and the drop follows a strong recent run (YTD +57.60%). Investors are focusing on an upcoming earnings announcement on 02 Mar 2026 and clinical-readout risks tied to Valbiotis SA’s pipeline.